LUCD - התחייבויות לטווח ארוך להון Lucid Diagnostics, Inc

Lucid Diagnostics Inc. (LUCD) specializes in non-invasive esophageal tumor detection for patients and physicians. This price chart illustrates the financial performance of this segment, where the metric stands at 0.05. The technology stack relies on automated systems and AI, although the final diagnosis is made by a physician. Management is currently focusing on developing sales and expanding the list of insurance programs to improve diagnostic accessibility.

This indicator measures the proportion of debt with a maturity of over one year relative to equity, determining the financial stability and debt load of the balance sheet structure. A decrease in the long-term debt-to-equity ratio confirms the company's reliability, which is critical for Lucid Diagnostics Inc. (LUCD) as it scales EsoGuard sales and anticipates the expansion of insurance coverage.